Korro (Nasdaq: KRRO) said CEO Ram Aiyar, Ph.D., will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026, at 11:10 a.m. ET. The event runs March 2–4, 2026, at the Boston Marriott Copley Place.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – KRRO
-0.33%
1 alert
-0.33%Session close to close
$117.34MMarket Cap
0.0xRel. Volume
In the Feb 26 session, KRRO declined 0.33%, reflecting a mild negative market reaction.
This announcement adds another investor-facing event to Korro’s busy calendar, with a TD Cowen prese...
Analysis
This announcement adds another investor-facing event to Korro’s busy calendar, with a TD Cowen presentation on March 3, 2026 at 11:10 a.m. ET. Recent history shows meaningful stock moves around conferences, analyst days, and earnings, including both double-digit gains and notable declines. Investors monitoring this name often focus on progress for KRRO-110 and KRRO-121, cash runway of $102.5M as of Q3 2025, workforce restructuring, and ongoing large-holder 13G filings as key context for future updates.
Participation in several investor and scientific conferences on RNA editing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Event- and conference-related news has often coincided with upside (moves of +7.77% and +17.25%), while a negative-leaning earnings update and an analyst day produced declines.
Recent Company History
In the past several months, Korro has mixed corporate and pipeline milestones with active investor outreach. A Q3 2025 update highlighted KRRO-110’s sub-threshold AAT levels and a pivot to a GalNAc-conjugated construct, alongside a $102.5M cash balance and workforce reduction, and the stock fell 4.21%. Subsequent participation in multiple conferences saw a strong 17.25% gain, and a J.P. Morgan presentation coincided with a 7.77% rise. An analyst day centered on KRRO-121 and regulatory plans was followed by a modest 2.28% decline. Today’s TD Cowen appearance fits this pattern of frequent investor-facing events.
"developing a new class of genetic medicines based on editing RNA for rare"
RNA editing is a natural or engineered process that changes the molecular message copied from a gene before it is used to make a protein, like tweaking a recipe after it’s written to alter the final dish. For investors, RNA editing matters because it enables new kinds of medicines and diagnostics — promising bigger returns but also carrying technical, safety and regulatory risks that can strongly affect a biotech company’s value.
restricted stock unitsfinancial
"He was granted 40,000 shares of common stock through restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock optionfinancial
"He was also granted a stock option for 80,000 shares of common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
schedule 13gregulatory
"has filed a Schedule 13G reporting a passive ownership stake"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
schedule 13g/aregulatory
"Point72-affiliated entities filed an amended Schedule 13G reporting a 2.9% passive"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
orphan drugregulatory
"Regulatory milestones include IND clearance, Fast Track, and Orphan Drug designations."
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
fast trackregulatory
"Regulatory milestones include IND clearance, Fast Track, and Orphan Drug"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar’s presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET.
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
When will Korro (KRRO) present at the TD Cowen 46th Annual Health Care Conference?
Korro will present on Tuesday, March 3, 2026, at 11:10 a.m. ET. According to the company, Ram Aiyar, Ph.D., CEO and President, is scheduled to deliver the presentation during the three-day conference running March 2–4, 2026.
Who from Korro (KRRO) will present at the TD Cowen 46th Annual Health Care Conference?
Ram Aiyar, Ph.D., Korro's CEO and President, will present at the conference. According to the company, Dr. Aiyar will speak on March 3, 2026, representing Korro at the Boston Marriott Copley Place event.
Where is the TD Cowen 46th Annual Health Care Conference where Korro (KRRO) will present?
The conference is held at the Boston Marriott Copley Place in Boston, MA. According to the company, the TD Cowen event runs March 2–4, 2026, with Korro's presentation scheduled for March 3, 2026, at 11:10 a.m. ET.
What will Korro (KRRO) likely discuss at the TD Cowen 46th Annual Health Care Conference?
Korro is expected to discuss its RNA editing genetic medicines for rare and prevalent diseases. According to the company, Korro develops a new class of genetic medicines based on editing RNA, which frames the likely presentation topics.
What is the date range of the TD Cowen 46th Annual Health Care Conference where Korro (KRRO) is attending?
The conference takes place March 2–4, 2026 in Boston. According to the company, Korro's CEO will present on March 3, 2026, during the multi-day TD Cowen event at the Boston Marriott Copley Place.
